Imprimis’ Ophthalmic Sales Grow 105 Percent in Q1-2017

May 12, 2017: By Jon Swedien

Imprimis’ ophthalmology-related sales in Q1-2017 totaled $3.7 million, a 105 percent increase over Q1-2016, the San Diego-based company reported May 10.

The company’s total revenues for Q1-2017 were $6.1 million, a 39 percent increase compared with Q1-2016, said Imprimis, a pharmaceutical company focused on increasing patient access and affordability to critical medicines.

Imprimis said its total sales for March were the highest monthly revenues recorded in the company’s history and represented a significant increase over previous months.

CEO Mark Baum attributed some of the company’s recent success to its US FDA-registered outsourcing facility—which began shipping products in February—that allows customers to order products without specific prescription information, enabling them to have an inventory of Imprimis products on hand.

Baum said sales were also bolstered because Imprimis had five ophthalmic formulations come online in March.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022